raloxifene   Click here for help

GtoPdb Ligand ID: 2820

Synonyms: Evista® | LY-156758 | Optruma® | raloxifene hydrochloride
Approved drug PDB Ligand
raloxifene is an approved drug (FDA (1997), EMA (1998))
Compound class: Synthetic organic
Comment: Raloxifene is a selective estrogen receptor modulator (SERM).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: raloxifene

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 98.24
Molecular weight 473.17
XLogP 5.65
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O
Isomeric SMILES Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O
InChI InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
No information available.
Summary of Clinical Use Click here for help
For the prevention and treatment of osteoporosis in post-menopausal women, and the prevention and treatment of corticosteroid-induced bone loss. Also used for the reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis or those who have a high risk of breast cancer development.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Estrogen receptor modulator, producing estrogen-like effects on bone which results in reduced resorption of bone and increased bone mineral density in postmenopausal women. For a complete overview of the mechanism of aciton of raloxifene, please see the DrugBank entry linked to from this ligand page.
External links Click here for help